Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1921. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. (Abstract)

Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Type 2 diabetes mellitus is associated with a heavy burden of suffering. Screening for diabetes is controversial.To examine the evidence that screening and earlier treatment are effective in reducing morbidity and mortality associated with diabetes.MEDLINE, the Cochrane Library, reviews, and experts, all of which addressed key questions about screening.Studies that provided information (...) about the existence and length of an asymptomatic phase of diabetes; studies that addressed the accuracy and reliability of screening tests; and randomized, controlled trials with health outcomes for various treatment strategies were selected.Two reviewers abstracted relevant information using standardized abstraction forms and graded articles according to U.S. Preventive Services Task Force criteria.No randomized, controlled trial of screening for diabetes has been performed. Type 2 diabetes

2003 Annals of Internal Medicine

1922. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. (Abstract)

Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Incidence data on which to base targets and protocols for screening for sight-threatening diabetic retinopathy are few. We aimed to investigate yearly and cumulative incidence of any retinopathy, maculopathy, and sight-threatening diabetic retinopathy in patients with type 2 diabetes in an established systematic programme and to calculate optimum screening intervals (...) according to retinopathy grade at baseline.We investigated all patients with type 2 diabetes registered with enrolled general practices (except those who were attending an ophthalmologist) who had retinopathy data available at baseline and at least one further screening event. To screen patients, we used non-stereoscopic three-field mydriatic photography and modified Wisconsin grading. Sight-threatening diabetic retinopathy was defined as moderate preproliferative retinopathy or worse, or clinically

2003 Lancet

1923. Adiponectin and protection against type 2 diabetes mellitus. (Abstract)

Adiponectin and protection against type 2 diabetes mellitus. Adiponectin is an adipocyte-derived peptide, which has anti-inflammatory and insulin-sensitising properties. We designed a nested case-control study to assess whether baseline adiponectin concentrations in plasma are independently associated with risk of type 2 diabetes. We found that adiponectin concentrations in plasma were lower among individuals who later developed type 2 diabetes than among controls (mean 5.34 microg/mL [SD 3.49 (...) ] vs 6.87 microg/mL [4.58], p<0.0001). High concentrations of adiponectin were associated with a substantially reduced relative risk of type 2 diabetes after adjustment for age, sex, waist-to-hip ratio, body-mass index, smoking, exercise, alcohol consumption, education, and glycosylated haemoglobin A(1c) (odds ratio 4th vs 1st quartile 0.3 [95% CI 0.2-0.7], p=0.0051). We conclude that adiponectin is independently associated with a reduced risk of type 2 diabetes in apparently healthy individuals.

2003 Lancet

1924. Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus. (Abstract)

Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus. In many places, children newly diagnosed with type 1 diabetes mellitus are admitted to hospital for metabolic stabilisation and training, even if they are not acutely ill. Out-patient or home based management of these children could avoid the stress associated with a hospital stay, could provide a more natural learning environment for the child and its family, and might reduce costs (...) for both the health care system and the families.To assess the effects of routine hospital admission compared to out-patient or home-based management in children newly diagnosed with type 1 diabetes who are not acutely ill, on metabolic control, wellbeing and self-efficacy of the patient and his/her family.We searched the Cochrane Library (including the Cochrane Controlled Trials Register), Medline, Embase, Cinahl, and the British Nursing Index. Additionally, we searched reference lists of relevant

2003 Cochrane

1925. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. Full Text available with Trip Pro

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. Cardiovascular disease causes severe morbidity and mortality in type 1 diabetes, although the specific risk factors and whether chronic hyperglycemia has a role are unknown. We examined the progression of carotid intima-media thickness, a measure of atherosclerosis, in a population with type 1 diabetes.As part of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the long-term (...) follow-up of the Diabetes Control and Complications Trial (DCCT), 1229 patients with type 1 diabetes underwent B-mode ultrasonography of the internal and common carotid arteries in 1994-1996 and again in 1998-2000. We assessed the intima-media thickness in 611 subjects who had been randomly assigned to receive conventional diabetes treatment during the DCCT and in 618 who had been assigned to receive intensive diabetes treatment.At year 1 of the EDIC study, the carotid intima-media thickness

2003 NEJM Controlled trial quality: uncertain

1926. Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. Full Text available with Trip Pro

Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. Weight loss programs on the Internet appear promising for short-term weight loss but have not been studied for weight loss in individuals at risk of type 2 diabetes; thus, the longer-term efficacy is unknown.To compare the effects of an Internet weight loss program alone vs with the addition of behavioral counseling via e-mail provided for 1 year to individuals at risk of type 2 (...) circumference (-7.2 [7.5] vs -4.4 [5.7] cm; P =.05).Adding e-mail counseling to a basic Internet weight loss intervention program significantly improved weight loss in adults at risk of diabetes.

2003 JAMA Controlled trial quality: uncertain

1927. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. Full Text available with Trip Pro

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.The primary end point of this open, parallel trial was a composite of death from (...) interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79).A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.Copyright

2003 NEJM Controlled trial quality: uncertain

1928. Screening for type 2 diabetes to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care

Screening for type 2 diabetes to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care Screening for type 2 diabetes to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care Screening for type 2 diabetes to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care Feig D S, Palda V A, Lipscombe L L, with the Canadian Task Force (...) on Preventive Health Care Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Feig D S, Palda V A, Lipscombe L L, with the Canadian Task Force on Preventive Health Care. Screening for type 2 diabetes to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. London, Ontario: Canadian Task Force on Preventive Health Care

2003 Health Technology Assessment (HTA) Database.

1929. Glargine insulin for the treatment of type 1 and type2 diabetes

Pichon Riviere A, Augustovski F, Ciapponi A, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Glargine insulin for the treatment of type 1 and type2 diabetes. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives The aim of this study was to summarise the available evidence on glargine insulin for the treatment of type 1 and type 2 diabetes. Authors' conclusions About 14% of diabetic patients would turn to basal insuline therapy (...) /drug therapy; Diabetes Mellitus, Type 2 /drug therapy; Hemoglobin A, Glycosylated /metabolism; Hypoglycemia /prevention & Insulin /therapeutic use /analogs & control; derivatives Language Published Spanish Country of organisation Argentina English Summary English summary available Address for correspondence Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina, Tel: +54 11 49 66 00 82, Fax: +54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32005000626 Date bibliographic record

2003 Health Technology Assessment (HTA) Database.

1930. Principles of screening for type 2 diabetes

Principles of screening for type 2 diabetes Principles of screening for type 2 diabetes Principles of screening for type 2 diabetes L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES). Principles of screening (...) for type 2 diabetes. Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 2003: 160 Authors' objectives (i) To assess the benefit of screening for type 2 diabetes in metropolitan France. (ii) To draw up proposals for implementing a screening programme. Authors' conclusions In view of the uncertain clinical and economic aspects, these guidelines should be implemented while studies are carried out specifically to verify the prevalence of undiagnosed diabetes, to assess the feasibility

2003 Health Technology Assessment (HTA) Database.

1931. Guidance on the use of glitazones for the treatment of type 2 diabetes

Guidance on the use of glitazones for the treatment of type 2 diabetes Guidance on the use of glitazones for the treatment of type 2 diabetes Guidance on the use of glitazones for the treatment of type 2 diabetes National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance (...) on the use of glitazones for the treatment of type 2 diabetes. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 63. 2003 Authors' objectives To provide guidance on the use of glitazones for the treatment of type 2 diabetes. This guidance replaces Technology Appraisal Guidance No.9 issued in August 2000 and Technology Appraisal Guidance No.21 issued in March 2001. Authors' conclusions Guidance: 1.1 For people with type 2 diabetes, the use of a glitazone as second

2003 Health Technology Assessment (HTA) Database.

1932. Screening for type 2 diabetes mellitus

, Rathore S S. Screening for type 2 diabetes mellitus. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 19. 2003 Authors' objectives To examine the evidence of the benefits and harms of screening and earlier treatment in reducing the complications of type 2 diabetes mellitus (DM-2). Authors' conclusions The evidence for screening for DM-2 is indirect and mixed. The strongest case for screening comes from earlier detection (...) Screening for type 2 diabetes mellitus Screening for type 2 diabetes mellitus Screening for type 2 diabetes mellitus Harris R P, Lux L J, Bunton A J, Sutton S F, Lohr K N, Donahue K P, Whitener B L, Rathore S S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harris R P, Lux L J, Bunton A J, Sutton S F, Lohr K N, Donahue K P, Whitener B L

2003 Health Technology Assessment (HTA) Database.

1933. Islet cell transplantation for the treatment of non-uremic type 1 diabetic patients with severe hypoglycemia

Islet cell transplantation for the treatment of non-uremic type 1 diabetic patients with severe hypoglycemia Islet cell transplantation for the treatment of non-uremic type 1 diabetic patients with severe hypoglycemia Islet cell transplantation for the treatment of non-uremic type 1 diabetic patients with severe hypoglycemia Guo B, Harstall C, Corabian P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Guo B, Harstall C, Corabian P. Islet cell transplantation for the treatment of non-uremic type 1 diabetic patients with severe hypoglycemia. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR Report - HTA 31. 2003 Authors' objectives The objectives of this report were to systematically review the medical literature on the efficacy/effectiveness and safety of islet cell transplantation for non-uremic type 1 diabetic patients

2003 Health Technology Assessment (HTA) Database.

1934. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes

Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes Gary T L, Genkinger J M, Guallar E, Peyrot M, Brancati F L CRD summary This review assessed the effects of educational and behavioural interventions on body weight and glycaemic control in patients with type 2 diabetes. The authors (...) concluded that these interventions can improve glycaemic control, but the evidence is not yet overwhelming. The studies used a variety of different interventions and produced different results, suggesting that the effect of the interventions may not be consistent. Authors' objectives To assess the effects of educational and behavioural interventions on body weight and glycaemic control in patients with type 2 diabetes. Searching MEDLINE was searched from 1966 to 1999 for studies published in the English

2003 DARE.

1935. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus

Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

1936. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes The Diabetes Prevention Program Research Group Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) Disparities, National Center for Research Resources General Clinical Research Center Program, the Office of Research on Women's Health, the Indian Health Service; the Centers for Disease Control and Prevention; the American Diabetes Association; Bristol Myers Squibb; and Parke-Davis Bibliographic details The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26(9): 2518-2523

2003 NHS Economic Evaluation Database.

1937. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus

Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus Ramsdell J W, Braunstein S N, Stephens J M, Bell C E, Botteman M F, Devine S T Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of first-line therapies aimed at achieving the glycaemic control recommended by the American Diabetes Association (ADA) in patients with Type 2 diabetes. The six therapies examined were: glipizide

2003 NHS Economic Evaluation Database.

1938. Cost-outcome benefits of fibrate therapy in type 2 diabetes

Cost-outcome benefits of fibrate therapy in type 2 diabetes Cost-outcome benefits of fibrate therapy in type 2 diabetes Cost-outcome benefits of fibrate therapy in type 2 diabetes Feher M D, Langley-Hawthorne C E, Byrne C D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The use of fibrate (Supralip 160 mg tablets) and statin therapies (pravastatin or simvastatin at 40 mg/day) to treat coronary heart disease (CHD) in patients with Type 2 diabetes. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population consisted of a hypothetical patient population with Type 2 diabetes who were suffering from dyslipidaemia. Setting The setting was unclear, but it was likely

2003 NHS Economic Evaluation Database.

1939. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes

Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes Brandle M, Davidson M B, Schriger DL, Lorber B, Herman W H Record Status This is a critical abstract of an economic (...) Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with Type 2 diabetes and LDL cholesterol levels of at least 100 mg/dL, with no history of myocardial infarction (MI), angina or chest pain. Setting The setting was unclear, but it was likely to have been secondary care. The economic analysis was conducted in the USA. Dates to which data relate The effectiveness and cost data were gathered from studies published between 1994

2003 NHS Economic Evaluation Database.

1940. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus

Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus Maetzel A, Ruof J, Covington M, Wolf A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Orlistat (Xenical(r)) for the treatment of patients with type-2 diabetes was compared to standard treatment (sulphonlyurea, metformin, or insulin) and weight management strategies (adherence to guidelines (ATG)). Orlistat was given at a dose of 120mg three times daily. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

2003 NHS Economic Evaluation Database.